Youwei Bi

1.5k total citations · 1 hit paper
25 papers, 768 citations indexed

About

Youwei Bi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Youwei Bi has authored 25 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Youwei Bi's work include Pharmacogenetics and Drug Metabolism (6 papers), Pharmaceutical studies and practices (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Youwei Bi is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Pharmaceutical studies and practices (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Youwei Bi collaborates with scholars based in United States, United Kingdom and Netherlands. Youwei Bi's co-authors include Yaning Wang, Richard Pazdur, Banu A. Karimi-Shah, Dinko Rekić, Badrul A. Chowdhury, Julia A. Beaver, Harpreet Singh, Atiqur Rahman, Pallavi S. Mishra‐Kalyani and Nicole Drezner and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Youwei Bi

22 papers receiving 757 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

2021 193 citations Erica C. Nakajima, Nicole Drezner et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Youwei Bi United States	14	307	275	225	89	72	25	768
Johanna N.H. Timmer-Bonte Netherlands	15	212 0.7×	523 1.9×	242 1.1×	71 0.8×	31 0.4×	38	910
Yasuhito Fujisaka Japan	17	272 0.9×	481 1.7×	247 1.1×	83 0.9×	27 0.4×	51	885
Michela Roberto Italy	19	343 1.1×	598 2.2×	294 1.3×	166 1.9×	87 1.2×	75	1.1k
Julia Lawrence United States	16	279 0.9×	656 2.4×	271 1.2×	175 2.0×	36 0.5×	31	1.3k
Maja J. De Jonge Netherlands	16	298 1.0×	449 1.6×	471 2.1×	114 1.3×	21 0.3×	43	849
Omar Y. Mian United States	19	269 0.9×	200 0.7×	385 1.7×	172 1.9×	21 0.3×	85	907
Karin M. Kazemier Netherlands	13	327 1.1×	145 0.5×	548 2.4×	175 2.0×	160 2.2×	21	1.2k
Geert A. Cirkel Netherlands	14	144 0.5×	279 1.0×	163 0.7×	160 1.8×	24 0.3×	29	576
Michael Xiang United States	16	295 1.0×	351 1.3×	475 2.1×	203 2.3×	23 0.3×	68	1.1k
Raimondo Di Liello Italy	13	228 0.7×	357 1.3×	265 1.2×	113 1.3×	34 0.5×	33	738

Countries citing papers authored by Youwei Bi

Since Specialization

Citations

This map shows the geographic impact of Youwei Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youwei Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youwei Bi more than expected).

Fields of papers citing papers by Youwei Bi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youwei Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youwei Bi. The network helps show where Youwei Bi may publish in the future.

Co-authorship network of co-authors of Youwei Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Youwei Bi. A scholar is included among the top collaborators of Youwei Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youwei Bi. Youwei Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Da, et al.. (2025). Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective. The Journal of Clinical Pharmacology. 66(1). e70104–e70104.

Chaudhri, Nadia, et al.. (2024). Approval of Mycophenolate Mofetil for Prophylaxis of Organ Rejection in Pediatric Recipients of Heart or Liver Transplants: A Regulatory Perspective. Clinical Pharmacology & Therapeutics. 116(3). 807–813. 2 indexed citations

Bi, Youwei, et al.. (2024). Potential Bias Evaluation of Conventional Exposure-Response Analysis.

Tsakalozou, Eleftheria, Lanyan Fang, Youwei Bi, et al.. (2024). Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products—a Meeting Report. The AAPS Journal. 26(1). 14–14. 3 indexed citations

Pisal, Dipak S., Amit Golding, Nikolay P. Nikolov, et al.. (2024). Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis. Clinical Pharmacology & Therapeutics. 117(2). 475–484. 3 indexed citations

Wang, Li, Jiang Liu, Justin Earp, et al.. (2023). Model‐Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective. The Journal of Clinical Pharmacology. 63(S2). S65–S77.

Akinboro, Oladimeji, Nicole Drezner, Anup Amatya, et al.. (2023). US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(17). 3249–3259. 23 indexed citations

Gandhy, Shruti U., Sandra J. Casak, Sirisha L. Mushti, et al.. (2023). FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements. Clinical Cancer Research. 29(20). 4027–4031. 11 indexed citations

Casak, Sandra J., M. Naomi Horiba, Mengdie Yuan, et al.. (2023). FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer. Clinical Cancer Research. 29(21). 4326–4330. 21 indexed citations

10.

Ye, Jingjing, Youwei Bi, & Naitee Ting. (2022). How to select the initial dose for a pediatric study?. Journal of Biopharmaceutical Statistics. 33(6). 844–858. 1 indexed citations

11.

Duke, Elizabeth S., Amy Barone, Pallavi S. Mishra‐Kalyani, et al.. (2022). FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer. Clinical Cancer Research. 28(19). 4173–4177. 36 indexed citations

12.

Nakajima, Erica C., Nicole Drezner, Xiaoxue Li, et al.. (2021). FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC. Clinical Cancer Research. 28(8). 1482–1486. 193 indexed citations breakdown →

13.

Bi, Youwei, Jiang Liu, Jingyu Yu, et al.. (2021). Model‐Informed Drug Development in Pediatric Dose Selection. The Journal of Clinical Pharmacology. 61(S1). S60–S69. 17 indexed citations

14.

Bi, Youwei, Dinko Rekić, Jianmeng Chen, et al.. (2020). A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. Journal of Pharmacokinetics and Pharmacodynamics. 48(1). 55–67. 5 indexed citations

15.

Bi, Youwei, Hong Zhao, Jiajie Yu, et al.. (2019). Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Annals of Oncology. 30(4). 644–651. 42 indexed citations

16.

Bi, Youwei, Jiang Liu, Jie Wang, et al.. (2019). Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective. The AAPS Journal. 21(5). 91–91. 39 indexed citations

17.

Pelosof, Lorraine, Steven J. Lemery, Sandra J. Casak, et al.. (2018). Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. The Oncologist. 23(4). 496–500. 15 indexed citations

18.

Shah, Anand, Erik Bloomquist, Shenghui Tang, et al.. (2018). FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clinical Cancer Research. 24(13). 2999–3004. 88 indexed citations

19.

Bi, Youwei, et al.. (2017). Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society. 14(9). 1395–1402. 124 indexed citations

20.

Bi, Youwei, Jiexin Deng, Daryl J. Murry, & Guohua An. (2015). A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. The AAPS Journal. 18(1). 228–238. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact